Published by Iain Gilbert on 19th October 2021
(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.
URL: http://www.digitallook.com/dl/news/story/32201079/...